Last reviewed · How we verify
Epoetin β (450 UI/kg/week)
Epoetin β is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Epoetin β is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia of chronic kidney disease, Anemia associated with chemotherapy in cancer patients, Anemia in patients with chronic diseases.
At a glance
| Generic name | Epoetin β (450 UI/kg/week) |
|---|---|
| Sponsor | Germans Trias i Pujol Hospital |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Epoetin β mimics the natural hormone erythropoietin, which regulates red blood cell production in response to tissue hypoxia. By binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes their proliferation, differentiation, and maturation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity of the blood.
Approved indications
- Anemia of chronic kidney disease
- Anemia associated with chemotherapy in cancer patients
- Anemia in patients with chronic diseases
Common side effects
- Hypertension
- Headache
- Thrombosis/thromboembolic events
- Injection site reactions
- Flu-like symptoms
- Pure red cell aplasia (rare)
Key clinical trials
- Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens (PHASE4)
- Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV (PHASE4)
- High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epoetin β (450 UI/kg/week) CI brief — competitive landscape report
- Epoetin β (450 UI/kg/week) updates RSS · CI watch RSS
- Germans Trias i Pujol Hospital portfolio CI